Tara Keihanian, MD
Gastroenterology · Houston, TXNPI 1255725735
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (32.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Conmed Corporation at 54.5% of the total. 2025 is the largest year on record at $7,577, more than ten times the $19 reported in 2020.
Across 133 payments — averaging $153.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Conmed Corporation$11K
- Boston Scientific$4K
- AbbVie$1K
- Creo Medical Inc.$558
- Applied Medical Resources Corporation$547
- Lumendi LLC$400
- plus $2K from 20 others
What the payments were for
- Consulting fees$6,65933%
- Speaking & faculty fees$4,00020%
- Travel & lodging$3,48517%
- Food & beverage$6,23731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Conmed Corporation | 10 | $11,108 |
| Boston Scientific | 37 | $3,994 |
| AbbVie | 39 | $1,497 |
| Creo Medical Inc. | 2 | $558 |
| Applied Medical Resources Corporation | 5 | $547 |
| Lumendi LLC | 1 | $400 |
| Apollo Endosurgery US Inc | 4 | $392 |
| 3-d Matrix, Inc. | 1 | $249 |
| Steris Corporation | 3 | $239 |
| Cook Medical LLC | 2 | $234 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $217 |
| Micro-tech Endoscopy USA, Inc. | 2 | $180 |
| Fujifilm Healthcare Americas Corporation | 1 | $141 |
| Amgen | 1 | $119 |
| Olympus Corporation Of The Americas | 1 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Medtronic | 1 | $56 |
| Johnson & Johnson | 2 | $50 |
| Endogastric Solutions, Inc | 1 | $50 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Merck | 2 | $37 |
| Ambu Inc. | 1 | $27 |
| Alcresta Therapeutics, Inc. | 1 | $25 |
| Sanofi | 1 | $20 |
| Mauna Kea Technologies, Inc. | 1 | $17 |
| QOL Medical, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEAMER SYSTEM$5,964
- CONMED GENERATORS$5,035
- Resolution 360 Clip$1,444
- GENERAL - THERAPIES$1,309
- SPEEDBOAT$558
- X-Tack Endoscopic HeliX Tacking System$426
- DILUMEN ENDOLUMENAL INTERVENTIONAL PLATFORM$400
- ORISE$396
- Hemospray$234
- Creon$222
- OverStitch Endoscopic Suturing System$213
- TRUFREEZE$206
- CONMED HEMOSTASIS$150
- CONMED BILIARY$150
- FUJIFILM$141
- XIFAXAN$133
- UPLIZNA$119
- EXALT Model D$116
- Mavyret$107
How this compares
$20,381 in reported general payments places this provider in the 85th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 53 | $223,274 |
| LinzessLinaclotide | 24 | $14,306 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 61 | $3,396 |
| Colesevelam Hcl | 22 | $2,825 |
| Omeprazole | 68 | $533 |
| Pregabalin | 23 | $489 |
| Dicyclomine Hcl | 26 | $408 |
| Famotidine | 22 | $168 |
| Citalopram HbrCitalopram Hydrobromide | 23 | $148 |
| Pantoprazole Sodium | 17 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,497 | $237,58177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Houston
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
- Brooks CashHouston$867K
- Mohamed OthmanHouston$777K
- Isaac RaijmanHouston$565K
- Kalpesh PatelHouston$382K
- Victor Ankoma-SeyHouston$340K
- John VierlingHouston$270K
- George TriadafilopoulosHouston$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.